Goldenwell Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 02:14 pm EDT
Share
Goldenwell Biotech, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.003713 million compared to USD 0.001106 million a year ago. Net loss was USD 0.0268 million compared to USD 0.023584 million a year ago.
For the six months, sales was USD 0.00411 million compared to USD 0.001106 million a year ago. Net loss was USD 0.06018 million compared to USD 0.069685 million a year ago.
Goldenwell Biotech, Inc. is in the development stage whose purpose is research and development, production and sales health cares and supplements products. The Company is offering its products under two categories: Polypeptide Freeze-dried Powder and Solid Tablets Products. The Companyâs products are JI MAI-Bovine Cardiac Vascular Active Peptide, Double Proline AG- three-dimensional (3D) Active Collagen Peptide, Cartilage Peptide-Type II collagen peptide, Se Plus, and Sugar Master. Bovine cardiac vascular active peptide is a protein peptide of vascular homology (amino acid type and its sequence) which made from healthy and fresh bovine cardiac vascular tissues as raw materials. Its DPAG product is designed to be an easily absorbed bioactive collagen. Type II collagen peptide is prepared from Bovine or Pig Cartilage bones by hot water extraction. Its Sugar Master product is made utilizing low temperature extraction techniques to maximize the harvest of bio-actives of plant matter.
GOLDENWELL BIOTECH, INC. 
